These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 28920531

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Ophiopogonin D' inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling.
    Xu T, Zhang W, Zhang Y, Song F, Huang P.
    J Cell Mol Med; 2024 Aug; 28(16):e70014. PubMed ID: 39153211
    [Abstract] [Full Text] [Related]

  • 23. Diallyl trisulphide, a H2 S donor, compromises the stem cell phenotype and restores thyroid-specific gene expression in anaplastic thyroid carcinoma cells by targeting AKT-SOX2 axis.
    Zhang L, Xu S, Cheng X, Zheng J, Wang Y, Wu J, Wang X, Wu L, Yu H, Bao J.
    Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
    [Abstract] [Full Text] [Related]

  • 24. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, Bartenstein P, Nelson PJ, Ogris M, Wagner E, Spitzweg C.
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [Abstract] [Full Text] [Related]

  • 25. miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via targeting homeobox A9.
    Zhang Y, Li K, Wang W, Han J.
    Int J Exp Pathol; 2021 Aug; 102(4-5):209-217. PubMed ID: 34719830
    [Abstract] [Full Text] [Related]

  • 26. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z, Banković J, Dinić J, Tsimplouli C, Sereti E, Dragoj M, Paunović V, Milovanović Z, Stepanović M, Tanić N, Dimas K, Pešić M.
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [Abstract] [Full Text] [Related]

  • 27. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
    Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A.
    Cancer Res; 2000 Feb 01; 60(3):650-6. PubMed ID: 10676649
    [Abstract] [Full Text] [Related]

  • 28. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 01; 39(5):2225-2234. PubMed ID: 29517103
    [Abstract] [Full Text] [Related]

  • 29. C5AR1-induced TLR1/2 pathway activation drives proliferation and metastasis in anaplastic thyroid cancer.
    Liu B, Sun Y, Geng T, Wang H, Wu Z, Xu L, Zhang M, Niu X, Zhao C, Shang J, Shang F.
    Mol Carcinog; 2024 Oct 01; 63(10):1938-1952. PubMed ID: 38934768
    [Abstract] [Full Text] [Related]

  • 30. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
    Patel PN, Yu XM, Jaskula-Sztul R, Chen H.
    Ann Surg Oncol; 2014 Dec 01; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
    [Abstract] [Full Text] [Related]

  • 31. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
    Zhang X, Liu L, Deng X, Li D, Cai H, Ma Y, Jia C, Wu B, Fan Y, Lv Z.
    Oncogene; 2019 Jan 01; 38(5):699-715. PubMed ID: 30171257
    [Abstract] [Full Text] [Related]

  • 32. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
    Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, Larijani B.
    Tumour Biol; 2016 Jan 01; 37(1):1299-308. PubMed ID: 26289851
    [Abstract] [Full Text] [Related]

  • 33. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
    J Clin Endocrinol Metab; 2012 Apr 01; 97(4):E528-36. PubMed ID: 22278419
    [Abstract] [Full Text] [Related]

  • 34. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
    Orlandella FM, Di Maro G, Ugolini C, Basolo F, Salvatore G.
    Oncotarget; 2016 Oct 25; 7(43):70575-70588. PubMed ID: 27661106
    [Abstract] [Full Text] [Related]

  • 35. miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma.
    Xu Y, Han YF, Ye B, Zhang YL, Dong JD, Zhu SJ, Chen J.
    Basic Clin Pharmacol Toxicol; 2018 Dec 25; 123(6):670-677. PubMed ID: 29924913
    [Abstract] [Full Text] [Related]

  • 36. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X, Zhang H, Xu X, Yu Y, Zhang H, Zhang J, Ning L, Hao F, Liu X, Niu M, Chen CT, Chen D, Zhang K.
    Cell Physiol Biochem; 2018 Dec 25; 49(3):1143-1162. PubMed ID: 30196299
    [Abstract] [Full Text] [Related]

  • 37. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
    Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH, Kim KH, Suh DS, Kim JH.
    Oncotarget; 2016 Jan 19; 7(3):3506-19. PubMed ID: 26654944
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.
    Clin Cancer Res; 2016 Dec 15; 22(24):6192-6203. PubMed ID: 27307592
    [Abstract] [Full Text] [Related]

  • 39. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K, Yu M, Hao F, Dong A, Chen D.
    Cancer Biomark; 2016 Sep 26; 17(3):281-291. PubMed ID: 27802204
    [Abstract] [Full Text] [Related]

  • 40. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
    Duz MB, Karatas OF.
    Mol Biol Rep; 2021 Feb 26; 48(2):1393-1400. PubMed ID: 33506275
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.